Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Shares Outstanding for 4 consecutive years, with $285.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 39.09% to $285.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.1 million through Dec 2025, up 39.09% year-over-year, with the annual reading at $285.1 million for FY2025, 39.09% up from the prior year.
  • Shares Outstanding hit $285.1 million in Q4 2025 for Taysha Gene Therapies, up from $273.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $285.1 million in Q4 2025 to a low of $38.5 million in Q1 2022.
  • Historically, Shares Outstanding has averaged $157.5 million across 4 years, with a median of $187.0 million in 2023.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 354.05% in 2023 and later grew 9.62% in 2024.
  • Year by year, Shares Outstanding stood at $63.2 million in 2022, then soared by 195.79% to $187.0 million in 2023, then rose by 9.62% to $204.9 million in 2024, then surged by 39.09% to $285.1 million in 2025.
  • Business Quant data shows Shares Outstanding for TSHA at $285.1 million in Q4 2025, $273.9 million in Q3 2025, and $272.7 million in Q2 2025.